Brokerages Set Galapagos NV (NASDAQ:GLPG) Target Price at $30.75

Galapagos NV (NASDAQ:GLPG) has been assigned an average recommendation of “Reduce” from the seven analysts that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and five have assigned a hold recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $30.75.

A number of brokerages have commented on GLPG. Kepler Capital Markets downgraded shares of Galapagos from a “hold” rating to a “reduce” rating in a research note on Wednesday, November 20th. Raymond James downgraded shares of Galapagos from an “outperform” rating to a “market perform” rating in a research note on Friday, August 2nd. Leerink Partners started coverage on shares of Galapagos in a research note on Monday, September 9th. They issued a “market perform” rating and a $24.00 price target on the stock. Leerink Partnrs raised shares of Galapagos to a “hold” rating in a research note on Monday, September 9th. Finally, Royal Bank of Canada reduced their price target on shares of Galapagos from $32.00 to $30.00 and set a “sector perform” rating on the stock in a research note on Friday, November 1st.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Creative Planning acquired a new position in shares of Galapagos in the second quarter valued at approximately $456,000. Crossmark Global Holdings Inc. acquired a new position in Galapagos during the 3rd quarter worth approximately $1,077,000. Signaturefd LLC grew its holdings in Galapagos by 65.6% during the 3rd quarter. Signaturefd LLC now owns 6,413 shares of the biotechnology company’s stock worth $185,000 after acquiring an additional 2,541 shares in the last quarter. Headlands Technologies LLC grew its holdings in Galapagos by 56.7% during the 2nd quarter. Headlands Technologies LLC now owns 1,233 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 446 shares in the last quarter. Finally, Stonepine Capital Management LLC grew its holdings in Galapagos by 23.2% during the 2nd quarter. Stonepine Capital Management LLC now owns 485,000 shares of the biotechnology company’s stock worth $12,018,000 after acquiring an additional 91,366 shares in the last quarter. Institutional investors and hedge funds own 32.46% of the company’s stock.

Galapagos Stock Down 1.5 %

Shares of GLPG stock opened at $26.90 on Friday. The firm’s 50-day moving average is $28.55 and its two-hundred day moving average is $27.48. Galapagos has a 12 month low of $24.16 and a 12 month high of $42.46.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.